Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics

Johnson & Johnson

Each has its own reason for being in your portfolio.

3 Top Healthcare Stocks to Buy Right Now

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, October 28, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

ResMed to Report First Quarter Fiscal 2022 Earnings on October 28, 2021

ResMed Inc.: Best Price-Positioned Medical Supply Industry Stock, As Seen By Market-Makers

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

Continued PAP use linked to 39% higher chance of survival over a 3-year period Continued PAP use linked to 39% higher chance of survival over a 3-year period

People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS

David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Pendarvis sold 1,487 shares of Resmed at a price of $292.16 per share.

Chief Administrative Officer Of Resmed Makes $434.44 Thousand Sell

James Hollingshead , President of  Resmed (NYSE: RMD ), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Hollingshead sold 2,400 shares of Resmed at a price of $287.3 per share.

President Of Resmed Makes $689.53 Thousand Sell

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021, beginning at approximately 1:15 p.m. (Eastern Daylight Time) via video webcast.

ResMed Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business

ResMed Announces SaaS Leadership Change

ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.

ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization

IDEXX Laboratories

Vertex Pharmaceuticals

It doesn't take a brainiac to balance risk and reward.

3 Smartest Healthcare Stocks to Buy With $1,000 Right Now

Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.

ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?

New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently

ResMed Launches AirSense 11 PAP Series, Advancing Digital Health in Sleep Apnea Treatment

Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.

ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down

ResMed Inc. (RMD) CEO Mick Farrell on Q4 2021 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 8.00% and 12.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q4 Earnings and Revenues Beat Estimates

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021

Apollo Medical Hlds

Canon

Tyler Technologies

Vista Outdoor

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. VSTO, CAJ, AMEH, TYL and RMD are the frontrunners.

Betting on These 5 Low-Beta Stocks is Ideal in a Choppy Market

East West Bancorp

HCA Healthcare

KLA-Tencor

Landstar System

Tivity Health

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

6 GARP Stocks to Scoop Up for Maximum Returns

Newell Brands

Teladoc

Uber

Microchip Technology

Magnolia Oil & Gas Corp

Rapid7

United States Cellular

With the trading day nearly halfway over, the broad markets were edging higher, led by the Nasdaq's gain of about 0.5%.

Monday Afternoon Analyst Upgrades and Downgrades: Newell Brands, Teladoc Health, Uber and More

Illinois Tool Works

Bonanza Creek Energy

Cable One

Standard Motor Products

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

5 Top Stocks to Buy With Dividends Set to Be Raised This Week

ResMed (RMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for ResMed (RMD): Will It Gain?

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ResMed (RMD) Q4 Earnings Expected to Decline

Alkermes

Aptargroup

Pacer US Export Leaders ETF

Tempur Sealy International

Vanguard S&P Small-Cap 600 Growth ETF

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.

7 Growth Stocks to Buy As Meme Stock Mania Fades

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2021 on Thursday, August 5, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

News for ResMed Stock (RMD)